Results 101 to 110 of about 8,937,523 (396)

Nomogram for predicting overall survival in stage II‐III colorectal cancer

Cancer Medicine, 2020
The overall survival (OS) of patients diagnosed with stage II‐III colorectal cancer (CRC) can vary greatly, even between patients with the same tumor stage.
Jungang Liu, Xiaoliang Huang, Wenkang Yang, Chan Li, Zhengtian Li, Chuqiao Zhang, Shaomei Chen, Guo-Bin Wu, Weishun Xie, Chunyin Wei, Chao Tian, Ling-xu Huang, Franco Jeen, Xianwei Mo, Weizhong Tang   +14 more
semanticscholar   +1 more source

Circulating histones as clinical biomarkers in critically ill conditions

FEBS Letters, EarlyView.
Circulating histones are emerging as promising biomarkers in critical illness due to their diagnostic, prognostic, and therapeutic potential. Detection methods such as ELISA and mass spectrometry provide reliable approaches for quantifying histone levels in plasma samples.
José Luis García‐Gimenez, Juan Carlos Ruiz‐Rodríguez, Ricard Ferrer, Raquel Durá, Antonio Artigas, Iván Bajaña, David Bolado López de Andujar, Irene Cánovas‐Cervera, Adrián Ceccato, Luis Chiscano‐Camón, Elena Climent‐Martinez, Georgia García Fernández, Gemma Goma, Verónica Monforte, Beatriz Quevedo‐Sánchez, Adolf Ruiz‐Sanmartín, Antonio Sierra‐Rivera, Nieves Carbonell Monleón   +17 more
wiley   +1 more source

Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction [PDF]

, 2013
Background: This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced adenocarcinoma of the oesophagogastric ...
Arnold, Dirk, Brenner, Baruch, Galle, Peter R., Gockel, Ines, Klautke, Gunther, Lang, Hauke, Möhler, Markus, Roessler, Hans-Peter, Rödel, Claus, Schimanski, Carl Christoph, Schmidberger, Heinz, Thomaidis, Thomas, Trarbach, Tanja   +12 more
core   +1 more source

Evaluating overall survival and competing risks of survival in patients with early‐stage breast cancer using a comprehensive nomogram

Cancer Medicine, 2020
Background Patients with early‐stage breast cancer (BC) live long but have competing comorbidities. This study aimed to estimate the effect of cancer and other causes of death in patients with early‐stage BC and further quantify the survival differences.
Yan‐Bo Xu, Hong Liu, Qi‐Hua Cao, Jia‐Li Ji, Rong‐Rong Dong, Dong Xu   +5 more
doaj   +1 more source

Adjuvant chemotherapy and overall survival in adult medulloblastoma [PDF]

Neuro-Oncology, 2016
Although chemotherapy is used routinely in pediatric medulloblastoma (MB) patients, its benefit for adult MB is unclear. We evaluated the survival impact of adjuvant chemotherapy in adult MB.Using the National Cancer Data Base, we identified patients aged 18 years and older who were diagnosed with MB in 2004-2012 and underwent surgical resection and ...
Joachim M. Baehring, Kenneth B. Roberts, Ranjit S. Bindra, Kevin P. Becker, Debra Nana Yeboa, Nataniel H. Lester-Coll, Jacqueline R. Kelly, Henry S. Park, Benjamin H. Kann, James B. Yu   +9 more
openaire   +3 more sources

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial

JAMA Oncology, 2018
Importance Anlotinib is a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling. A phase 2 trial showed anlotinib to improve progression-free survival with a potential benefit of overall survival, leading to the ...
B. Han, Kai Li, Qiming Wang, Li Zhang, Jianhua Shi, Zhehai Wang, Ying Cheng, Jianxing He, Yuankai Shi, Yizhuo Zhao, Hao Yu, Yang Zhao, Weiqiang Chen, Yi Luo, Lin Wu, Xiuwen Wang, R. Pirker, K. Nan, F. Jin, Jian Dong, Baolan Li, Yan Sun   +21 more
semanticscholar   +1 more source

Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer

JAMA Network Open, 2020
This systematic review and meta-analysis evaluates whether progression-free survival is a validated surrogate end point for overall survival in patients with advanced ovarian cancer.
X. Paoletti, L. Lewsley, G. Daniele, A. Cook, N. Yanaihara, A. Tinker, G. Kristensen, P. Ottevanger, G. Aravantinos, Austin Miller, I. Boere, R. Fruscio, A. Reyners, E. Pujade-Lauraine, A. Harkin, S. Pignata, T. Kagimura, S. Welch, J. Paul, E. Karamouza, R. Glasspool   +20 more
semanticscholar   +1 more source

The epithelial barrier theory proposes a comprehensive explanation for the origins of allergic and other chronic noncommunicable diseases

FEBS Letters, EarlyView.
Exposure to common noxious agents (1), including allergens, pollutants, and micro‐nanoplastics, can cause epithelial barrier damage (2) in our body's protective linings. This may trigger an immune response to our microbiome (3). The epithelial barrier theory explains how this process can lead to chronic noncommunicable diseases (4) affecting organs ...
Can Zeyneloglu, Huseyn Babayev, Ismail Ogulur, Sena Ardicli, Yagiz Pat, Duygu Yazici, Bingjie Zhao, Lihong Chang, Xiaoqing Liu, Paolo D'Avino, Manru Li, Ceren Biçer, Fatma Hacer Kurtoğlu Babayev, Raja Dhir, Kari C. Nadeau, Marie‐Charlotte Brüggen, Mubeccel Akdis, Cezmi A. Akdis   +17 more
wiley   +1 more source

MRI radiomic features are independently associated with overall survival in soft tissue sarcoma [PDF]

, 2019
Purpose: Soft tissue sarcomas (STS) represent a heterogeneous group of diseases, and selection of individualized treatments remains a challenge. The goal of this study was to determine whether radiomic features extracted from magnetic resonance (MR ...
Ball, Kevin C, Chapman, Tobias R, Combs, Stephanie E, Hippe, Daniel S, Hoff, Michael N, Kim, Edward Y, Macomber, Meghan W, Nyflot, Matthew J, Peeken, Jan C, Pollack, Seth M, Spraker, Matthew B, Wootton, Landon S   +11 more
core   +2 more sources

Durvalumab supplementation for non-small-cell lung cancer: a meta-analysis study

Journal of Cardiothoracic Surgery
Background Durvalumab supplementation may have some potential in improving the efficacy in patients with non-small-cell lung cancer (NSCLC), and this meta-analysis aims to explore the impact of durvalumab supplementation on efficacy for NSCLC.
Chengchen Wang, Hongyi Fu, Feng Wang
doaj   +1 more source